The present invention relates to coating compositions which comprise a silazane polymer (A), a silane coupling agent (B); and inorganic nanoparticles (C), wherein the components (A), (B) and (C) are present in certain ratios. The coating compositions are particularly suitable for the preparation of hard coatings on surfaces of various base material substrates.
C09D 183/16 - Coating compositions based on macromolecular compounds obtained by reactions forming in the main chain of the macromolecule a linkage containing silicon, with or without sulfur, nitrogen, oxygen, or carbon only; Coating compositions based on derivatives of such polymers in which all the silicon atoms are connected by linkages other than oxygen atoms
The present application relates to a compound of the formula (I), to the use thereof in electronic devices, to processes for preparing the compound, and electronic devices comprising the compound.
C07D 209/70 - [b]- or [c]-condensed containing carbocyclic rings other than six-membered
C07D 307/94 - Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom spiro-condensed with carbocyclic rings or ring systems, e.g. griseofulvins
C07D 333/78 - Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
H10K 50/11 - OLEDs or polymer light-emitting diodes [PLED] characterised by the electroluminescent [EL] layers
The present invention relates to heteroaromatic compounds suitable for use in electronic devices, and to electronic devices, in particular organic electroluminescent devices, containing said compounds.
C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
The present application relates to compounds of a formula (I), (II) or (III), to processes for preparing such compounds, and to electronic devices comprising one or more such compounds, and to the use of such compounds in electronic devices.
C07C 211/57 - Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings being part of condensed ring systems of the carbon skeleton
The present application relates to triarylamine compounds of a defined formula. The present application further relates to processes for preparing the compounds, to the use of the compounds in electronic devices, and to electronic devices comprising the compounds.
H10K 85/60 - Organic compounds having low molecular weight
C07D 209/86 - Carbazoles; Hydrogenated carbazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the ring system
C07D 209/88 - Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 409/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
The present invention relates to compounds which are suitable for use in electronic devices, and to electronic devices, in particular organic electroluminescent devices, containing these compounds.
C07D 413/10 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
C07D 417/10 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing aromatic rings
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 419/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
The invention relates to compounds which are suitable for use in electronic devices, and electronic devices, in particular organic electroluminescent devices, containing said compounds.
H10K 85/60 - Organic compounds having low molecular weight
C07D 209/56 - Ring systems containing three or more rings
C07D 307/77 - Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 403/10 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing aromatic rings
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 405/04 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 405/10 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
C07D 409/10 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
C07D 409/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
C07D 491/048 - Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
C09K 11/02 - Use of particular materials as binders, particle coatings or suspension media therefor
8.
IMPROVED TREATMENT METHODS USING DMDS FOR THE TREATMENT OF AUTOIMMUNE DISEASES, AND BIOMARKER FOR PREDICTING AND/OR OPTIMISING SAID TREATMENT METHODS
The invention pertains to improved treatment methods using DMDS, in particular cladribine, for the treatment of autoimmune diseases, in particular multiple sclerosis, and biomarkers, in particular immune cell subtypes, for predicting and/or optimising said treatment methods. The methods described rely on the use of immune cell subtypes, in particular T cells, B cells, NK cells subtypes and their ratios as present in blood samples from the patients for predicting and/or optimising the use of cladribine in the treatment of multiple sclerosis.
The present invention relates to liquid-crystal (LC) media as defined in claim 1, to the use thereof for optical, electro-optical and electronic purposes, in particular in LC displays, and to LC displays containing said LC media. The invention in particular relates to LC media with improved response time that enable energy saving displays.
C09K 19/30 - Non-steroidal liquid crystal compounds containing at least two non-condensed rings containing saturated or unsaturated non-aromatic rings, e.g. cyclohexane rings
The present invention relates to a liquid crystal medium comprising aromatic isothiocyanates of formula C
The present invention relates to a liquid crystal medium comprising aromatic isothiocyanates of formula C
The present invention relates to a liquid crystal medium comprising aromatic isothiocyanates of formula C
as defined in claim 1, and to high-frequency components comprising these media, especially microwave components for high-frequency devices, such as devices for shifting the phase of microwaves, tunable filters, tunable metamaterial structures, and electronic beam steering antennas, e.g. phased array antennas.
The present invention describes carbazole, dibenzofuran, dibenzothiophene and fluorene derivatives which are substituted by electron-deficient heteroaryl groups, in particular for use as triplet matrix materials in organic electroluminescent devices. The invention furthermore relates to a process for the preparation of the compounds according to the invention and to electronic devices comprising these compounds.
H10K 85/60 - Organic compounds having low molecular weight
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 409/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
C07D 407/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 251/24 - Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to three ring carbon atoms
C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 405/04 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 405/10 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
C07D 409/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
The present invention relates to novel positive tone photoresist formulations comprising using crosslinkable siloxane polymers. The siloxane polymers used in the positive tone photoresist formulations are crosslinkable and comprise a first repeating unit, which contains at least one maleimide group, and a second repeating unit, which does not contain a maleimide group. The present invention further provides a manufacturing method for a microelectronic structure using a positive tone photoresist formulation according to the present invention and to an electronic device comprising a microelectronic structure, which is obtained or obtainable by said manufacturing method.
System for performing a media preparation process controlled by a computer (7) further comprising a Media Preparation Module (12), a media bag (2) for storing the media in an unprepared state (13), a Dispensing Module (9, 9a) for storing the media in a finally prepared state (17), and a water providing system which connects the Media Preparation Module (12) with the media bag (2) and the Dispensing Module (9, 9a) and provides them with temperature adjustable water using a water sterilization filter set (4) wherein, the system (6) additionally comprises an attachable machine readable data storage (3) which contains information about the current state and/or operating parameters of the system parts, which are read, processed and used by the computer (7) to operate the system (6) according to required conditions.
The new media exhibit a ferroelectric nematic phase preferably at ambient temperature. They preferably comprise one or more compounds selected from the group of compounds of formulae IA, IB and IC,
The new media exhibit a ferroelectric nematic phase preferably at ambient temperature. They preferably comprise one or more compounds selected from the group of compounds of formulae IA, IB and IC,
The new media exhibit a ferroelectric nematic phase preferably at ambient temperature. They preferably comprise one or more compounds selected from the group of compounds of formulae IA, IB and IC,
in which the variable groups have the meanings indicated in the text and in the claims. Use of the media for providing ferroelectric nematic materials and a method of operation of an electro-optical device are presented. The media may be useful for energy-saving displays and electrical appliances.
C09K 19/20 - Non-steroidal liquid crystal compounds containing at least two non-condensed rings containing at least two benzene rings linked by a chain containing carbon and oxygen atoms as chain links, e.g. esters
C09K 19/30 - Non-steroidal liquid crystal compounds containing at least two non-condensed rings containing saturated or unsaturated non-aromatic rings, e.g. cyclohexane rings
C09K 19/34 - Non-steroidal liquid crystal compounds containing at least one heterocyclic ring
The present invention relates to compounds of the formula (1) which are suitable for use in electronic devices, and to electronic devices, in particular organic electroluminescent devices, containing these compounds.
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
New compounds and their mixtures enable the formation of the ferroelectric nematic liquid crystalline phase at ambient temperature. Compounds of the formula I are presented,
New compounds and their mixtures enable the formation of the ferroelectric nematic liquid crystalline phase at ambient temperature. Compounds of the formula I are presented,
in which the variable groups have the meanings indicated in claim 1. Liquid crystal media comprise at least one compound of the formula I.
C09K 19/20 - Non-steroidal liquid crystal compounds containing at least two non-condensed rings containing at least two benzene rings linked by a chain containing carbon and oxygen atoms as chain links, e.g. esters
C07C 255/54 - Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and etherified hydroxy groups bound to the carbon skeleton
C07C 255/55 - Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and esterified hydroxy groups bound to the carbon skeleton
C09K 19/34 - Non-steroidal liquid crystal compounds containing at least one heterocyclic ring
C09K 19/02 - Liquid crystal materials characterised by optical, electrical or physical properties of the components, in general
23.
POSITIVE-WORKING PHOTORESIST COMPOSITION WITH IMPROVED PATTERN PROFILE AND DEPTH OF FOCUS (DOF)
The disclosed subject matter relates to resist compositions that include the following components: Component a) a blend of two Novolak polymers having structures (I) and (II); component b) a diazo-naphthoquinone sulfonate (DNQ-PAC) component which is a single material or a mixture of materials having general formula having structure (III) or having general formula (III-1); is a dissolution enhancer component comprising a polyphenolic compound which is a single compound or a mixture of at least two compounds selected from the group consisting of an oligomeric fractionated Novolak, a compounds having general structure (VI) and a compound having general structure (VII), wherein Rde1, Rde2, Rde3, Rde4 and Rde5 are individually selected from a C-1 to C-4 alkyl; component d) a surfactant; and component e) an organic spin casting solvent, and an optional component f) a heterocyclic thiol.
[Problem] To provide a method for manufacturing a thickened resist pattern. [Means for Solution] A method for manufacturing a thickened resist pattern comprising the following steps: (1) applying a resist composition above a substrate to form a resist layer from the resist composition; (2a) exposing the resist layer; (2b) applying a thickening solution comprising a polymer (A) and a solvent (B) on the resist layer to form a thickening layer; and (3) developing the resist layer and the thickening layer.
G03F 7/11 - Photosensitive materials - characterised by structural details, e.g. supports, auxiliary layers having cover layers or intermediate layers, e.g. subbing layers
G03F 7/38 - Treatment before imagewise removal, e.g. prebaking
A method for processing digital image recognition of invariant representations of hierarchically structured entities can be performed by a computer using an artificial neural network. The method involves learning a sparse coding dictionary on an input signal to obtain a representation of low-complexity components. Possible transformations are inferred from the statistics of the sparse representation by computing a correlation matrix. Eigenvectors of the Laplacian operator on the graph whose adjacency matrix is the correlation matrix from the previous step are computed. A coordinate transformation is performed to the base of eigenvectors of the Laplacian operator, and the first step is repeated with the next higher hierarchy level until all hierarchy levels of the invariant representations of the hierarchically structured entities are processed and the neural network is trained. The trained artificial neural network can then be used for digital image recognition of hierarchically structured entities.
Tetrahydropyrido[3,4-d]pyrimidines compounds are provided that are potent HPK1 inhibitors. The compounds are useful to treat or prevent cancer and/or inflammatory and/or autoimmune diseases or symptoms thereof in mammals, particularly humans. The compounds have a chemical structure of the general Formula (I), (II), (III), (IV) or (V) or enantiomers or diastereomers or mixtures thereof or pharmaceutically acceptable salts thereof.
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
27.
METHOD FOR EVALUATION OF A THIN-LAYER CHROMATOGRAPHY PLATE
A method for evaluation of a thin-layer chromatography plate after performing a separation process that separates components of a sample on the thin-layer chromatography plate comprises a digitization step, wherein at least two digital images are taken that differ with respect to the wavelength range of illumination of the thin-layer chromatography plate. The method further comprises a position identification step wherein the position of the thin-layer chromatography plate is identified for each of the at least two digital images. Furthermore, the method comprises an evaluation step wherein an image information of the at least two digital images is superimposed for at least all regions with at least one visible spot within at least one of the at least two digital images, so that the superimposition of image information from identical regions of at least two digital images can be used for evaluation of the thin-layer chromatography.
The disclosed subject matter relates compounds of structure (I), and polymers of structure (II) having a polydispersity ranging from 1 to about 1.1, compositions comprising said polymers and a spin casting solvent, the process of forming a pinning layer el selectively on metal with said composition and the process of using said pinning layers to affect chemoepitaxy directed self-assembly of an overlying block copolymer, and the subsequent process of pattern transfer of this self-assembled layer into a substrate by etching.
The disclosed subject matter relates compounds of structure (I), and polymers of structure (II) having a polydispersity ranging from 1 to about 1.1, compositions comprising said polymers and a spin casting solvent, the process of forming a pinning layer el selectively on metal with said composition and the process of using said pinning layers to affect chemoepitaxy directed self-assembly of an overlying block copolymer, and the subsequent process of pattern transfer of this self-assembled layer into a substrate by etching.
The present invention relates to a new class of dielectric polymer material, which is particularly suitable for the manufacturing of electronic devices. The dielectric polymer material is formed by reacting bismaleimide compounds and shows an advantageous well-balanced profile of favorable material properties. The bismaleimide compounds have an oligomeric structure with a cardo and/or spiro moiety containing repeating unit in the middle part of the molecule and maleimide groups at each terminal end of the molecule. There is further provided a method for forming said dielectric polymer material and an electronic device comprising the same as dielectric material.
Antibodies which bind human CEACAM5 protein, as well as isolated nucleic acids and host cells containing a sequence encoding said antibodies are disclosed. Immunoconjugates containing said antibodies linked to a growth-inhibitory agent, and pharmaceutical compositions containing antibodies or said immunoconjugates are also disclosed. A use of the antibodies, immunoconjugates, and pharmaceutical compositions disclosed herein is provided for the treatment of cancer or for diagnostic purposes.
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
Methods of administering a therapeutically effective amount of Debio 1143 and a therapeutically effective amount of an anti-PD-L1 antibody or antigen-binding fragment thereof, for the treatment of cancer, are provided.
A61K 31/407 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with heterocyclic ring systems, e.g. ketorolac, physostigmine
A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
The present invention is directed toward edible hollow fibers and cartridges and bioreactors comprising the hollow fibers of the present invention, as well as, methods of production of structured clean meat products produced with the hollow fibers, cartridges and bioreactors of the present invention and the structured clean meat products produced by said methods. The macroscopic structure of structured clean meat grown on edible hollow fibers will result in a unique final structure. This final structure will contain a finite amount of fibers per unit area; with meat on the outside of the fibers.
Substituted tetrazole derivatives are useful for the prevention and/or treatment of several medical conditions including hyperproliferative disorders and diseases.
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/444 - Non-condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
A61K 31/506 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/501 - Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
A61K 9/02 - Suppositories; Bougies; Bases for suppositories or bougies
A61K 47/44 - Oils, fats or waxes according to two or more groups of ; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
A61K 41/17 - Inactivation or decontamination of a medicinal preparation prior to administration to an animal or a person by ultraviolet [UV] or infrared [IR] light, X-rays or gamma rays
The present application relates to biotechnological fluid treating, such as biopharmaceutical liquids in order to obtain products such as monoclonal antibodies, vaccines or recombinant proteins, and particularly to a system for treating a biotechnical fluid, having a bioprocess machine and at least one bioprocess machine helper, configured to connect to each other and each comprising a controller, in turn comprising a machine-to-machine communication tool configured for connecting to a network.
The invention pertains to the field of diagnostic tools for the detection of Schistosoma infection. The invention pertains to proteins derived from Schistosoma Haematobium antigens, useful alone or in combination for the detection of anti-Schistosoma antibodies in biological samples, and thus for the diagnosis of Schistosoma infection in humans.
The present application relates to an electronic device comprising a xanthene or thioxanthene compound of a particular formula. The electronic device is preferably an organic electroluminescent device (OLED). The application further relates to particular xanthene or thioxanthene compounds as such, and to the use thereof in the abovementioned devices, and to processes for preparation thereof.
H10K 85/60 - Organic compounds having low molecular weight
C07D 311/96 - Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings spiro-condensed with carbocyclic rings or ring systems
C07D 335/04 - Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
C07D 405/04 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 407/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 409/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
The disclosed subject matter relates to a block polymer comprising structure (1): (A)-(C)-(B), wherein (A) is a first polymer block segment comprising a block segment selected from structure (1a), structure (1b), and a mixture of structures (1a) an (1b), (C) is a spacer moiety comprising structure (1c); and wherein B) is a second polymer block segment comprising repeat units derived from either an alkyl 2-methylenealkanoate, a lactone; a cyclic carbonate, an oxirane, or an oxetane. The disclose matter also pertains to a composition of said block polymer in a spin casting solvent and using this solution in a process of directed self-assembly.
C08F 297/02 - Macromolecular compounds obtained by successively polymerising different monomer systems using a catalyst of the ionic or coordination type without deactivating the intermediate polymer using a catalyst of the anionic type
G03F 7/00 - Photomechanical, e.g. photolithographic, production of textured or patterned surfaces, e.g. printed surfaces; Materials therefor, e.g. comprising photoresists; Apparatus specially adapted therefor
C09D 153/00 - Coating compositions based on block copolymers containing at least one sequence of a polymer obtained by reactions only involving carbon-to-carbon unsaturated bonds; Coating compositions based on derivatives of such polymers
A liquid-crystal (LC) material having negative dielectric anisotropy and the use thereof for optical, electro-optical and electronic purposes, such as for example in LC displays, in particular energy saving displays based on the ECB, IPS or FFS effect, where the liquid crystal medium contains one or more compounds of formula I
A liquid-crystal (LC) material having negative dielectric anisotropy and the use thereof for optical, electro-optical and electronic purposes, such as for example in LC displays, in particular energy saving displays based on the ECB, IPS or FFS effect, where the liquid crystal medium contains one or more compounds of formula I
A liquid-crystal (LC) material having negative dielectric anisotropy and the use thereof for optical, electro-optical and electronic purposes, such as for example in LC displays, in particular energy saving displays based on the ECB, IPS or FFS effect, where the liquid crystal medium contains one or more compounds of formula I
and one or more compounds compounds of formulae IIA, IIB, IIC and IID
A liquid-crystal (LC) material having negative dielectric anisotropy and the use thereof for optical, electro-optical and electronic purposes, such as for example in LC displays, in particular energy saving displays based on the ECB, IPS or FFS effect, where the liquid crystal medium contains one or more compounds of formula I
and one or more compounds compounds of formulae IIA, IIB, IIC and IID
The present invention relates to a composition including at least one sulfosalicylic acid having structure (I), or its hydrate, and mixtures thereof and a sulfosalicylic acid having structure (I), or its hydrate, a primary solvent selected from acetone, and methyl ethyl ketone, or a mixture of these solvents, an optionally a secondary solvent which is a glycolic derivative, or a mixture of at least two glycolic derivatives, and an optional surfactant.
The present invention relates to a composition including at least one sulfosalicylic acid having structure (I), or its hydrate, and mixtures thereof and a sulfosalicylic acid having structure (I), or its hydrate, a primary solvent selected from acetone, and methyl ethyl ketone, or a mixture of these solvents, an optionally a secondary solvent which is a glycolic derivative, or a mixture of at least two glycolic derivatives, and an optional surfactant.
C09D 11/50 - Sympathetic, colour-changing or similar inks
C09D 11/037 - Printing inks characterised by features other than the chemical nature of the binder characterised by the pigment
C09D 11/101 - Inks specially adapted for printing processes involving curing by wave energy or particle radiation, e.g. with UV-curing following the printing
C09D 11/107 - Printing inks based on artificial resins containing macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds from unsaturated acids or derivatives thereof
The new LC media exhibit a ferroelectric nematic phase at ambient temperature. They comprise at least one or more compounds selected from each of formula IA, of formula IB and of the group of formulae IC-1/IC-2/IC-3,
The new LC media exhibit a ferroelectric nematic phase at ambient temperature. They comprise at least one or more compounds selected from each of formula IA, of formula IB and of the group of formulae IC-1/IC-2/IC-3,
The new LC media exhibit a ferroelectric nematic phase at ambient temperature. They comprise at least one or more compounds selected from each of formula IA, of formula IB and of the group of formulae IC-1/IC-2/IC-3,
in which the variable groups have the meanings indicated in the text and in the claims. The mixtures are useful for electro-optics, electronics, electro-mechanic and other applications for materials with very high dielectric permittivity and other energy-saving applications.
Described herein is a sample holder for use in the Crystalline Sponge (CS) method of introducing an analyte in a CS crystalline material for for use during the entire method of soaking (i.e. introducing the analyte into the crystallographic structure analysis of the analyte. The sample holder is suitable CS crystalline material and any subsequent steps including the X-ray crystallographic analysis of the material.
A method is disclosed for the preparation of a silicon nitrogeneous film. Polysilazane film is exposed to an electron beam irradiation and subsequently to at least one process selected from the group consisting of a vacuum ultra-violet light irradiation and a plasma processing. The treated film is heated under a non-oxidizing atmosphere to manufacture a silicon nitrogeneous film. The silicon nitrogeneous film is able to be formed at low process temperature. Further, the silicon nitrogeneous film has a high refractive index and low oxygen content.
The present invention relates to sulfurous compounds which are suitable for use in electronic devices, and to electronic devices, in particular organic electroluminescent devices containing said compounds.
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
45.
COVER FOR A THIN-LAYER CHROMATOGRAPHY DEVELOPMENT CHAMBER
A thin-layer chromatography development chamber (1) that can be used for developing thin-layer chromatography plates (21) by introducing a liquid solvent onto a sample arranged on the surface of a thin-layer chromatography plate (21), whereby the solvent and the thin-layer chromatography plate (21) can be inserted into the development chamber (1), comprises a housing (2) with an opening (3). The opening (3) of the development chamber (1) can be closed with a cover (4) that comprises a data input unit (10) for entering or collecting data related to a development process performed within the development chamber (1). The cover (4) further comprises a data communication unit (16) that enables a wireless data transmission of the data related to the development process to a thin-layer chromatography data storage device (24).
The present invention relates to heterocyclic compounds which are suitable for use in electronic devices, and to electronic devices, in particular organic electroluminescent devices, containing said compounds.
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
C07D 487/22 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups in which the condensed system contains four or more hetero rings
H10K 85/60 - Organic compounds having low molecular weight
H10K 50/11 - OLEDs or polymer light-emitting diodes [PLED] characterised by the electroluminescent [EL] layers
A polymerizable compound having absorption in the long UV wavelength range, a liquid-crystal (LC) medium comprising the polymerizable compound, and the use of the compound or LC medium for optical, electro-optical and electronic purposes, in particular in LC displays, especially in LC displays of the PSA (polymer sustained alignment) or SA (self-aligning) mode, an LC display of the PSA or SA mode comprising the compound or LC medium, and a process of manufacturing the LC display.
The present invention relates to a process for the variable adjustment of the electrical insulation properties of varistor-containing composite materials with the aid of defined filler mixtures, to the use of such filler mixtures, and to composite materials having resistive and capacitive field-control properties comprising filler mixtures of this type.
The present invention relates to a combination of a) a poxvirus vector encoding at least human papillomavirus (HPV) E6 and E7 polypeptides and an immunostimulatory cytokine, and b) an anti-PD-L1 antibody or antigen-binding fragment thereof, for use in the treatment of an HPV-positive cancer, wherein a first administration of said poxvirus is performed 5 to 10 days before the first administration of said anti-PD-L1 antibody, and subsequent administrations of said poxvirus and anti-PD-L1 antibody are performed.
The present application relates to compounds of the formula (I) or (II), to processes for preparing such compounds, and to electronic devices comprising one or more such compounds, and to the use of such compounds in electronic devices.
H10K 85/60 - Organic compounds having low molecular weight
C07C 211/61 - Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings being part of condensed ring systems of the carbon skeleton with at least one of the condensed ring systems formed by three or more rings
C07D 209/88 - Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
52.
ATOMIC LAYER ETCHING OF METAL OXIDES USING NOVEL CO-REACTANTS AS HALOGENATING AGENTS FOR SEMICONDUCTOR FABRICATION
The disclosed and claimed subject matter relates to thermal ALE processing of metal oxide films using one or more fluorinating agent and one or more chlorinating agent.
H01L 21/324 - Thermal treatment for modifying the properties of semiconductor bodies, e.g. annealing, sintering
H01L 23/532 - Arrangements for conducting electric current within the device in operation from one component to another including external interconnections consisting of a multilayer structure of conductive and insulating layers inseparably formed on the semiconductor body characterised by the materials
53.
METHOD FOR PRODUCING AN AMORPHOUSE SOLID DISPERSION AND PHARMACEUTICAL COMPOSITION FOR STABILIZING ACTIVE PHARMACEUTICAL INGREDIENTS
The present invention relates to a method for producing an amorphous solid dispersion of at least one active pharmaceutical ingredient in a polymer matrix. The Invention further relates to a pharmaceutical composition using polymers as an excipient and particularly to an improved pharmaceutical composition comprising polyvinyl alcohol grades with different degrees of hydrolysis, which is suitable to stabilize active pharmaceutical ingredients.
A liquid-crystal (LC) medium based on a mixture of polar compounds, its use for optical, electro-optical and electronic purposes, in particular in LC displays, especially in LC displays of the vertically aligned mode, to an LC display of the vertically aligned mode containing the LC medium, especially an energy-saving LC display and a process of manufacturing the LC display.
The application relates to a cartridge for a plurality of petri-dishes, comprising a cylindrical cartridge housing configured to receive the plurality of petri-dishes in a stack aligned with an axial direction of the cartridge housing in an interior space of the cartridge housing such that the stack of petri-dishes can be moved in the axial direction within the interior space. An axial end portion of the cartridge housing has a first opening dimensioned so that the petri-dishes can be exposed from the cartridge housing by sliding in the axial direction. Another axial end portion of the cartridge housing has a second opening dimensioned to prevent removal of the petri-dishes through the second opening and so that a piston can be inserted into the interior space of the cartridge housing for moving the stack of petri-dishes (P) in the axial direction towards the first opening.
The present invention relates to a compound of formula T
The present invention relates to a compound of formula T
The present invention relates to a compound of formula T
as defined in claim 1, to a liquid crystal medium comprising a compound of formula T and to high-frequency components comprising these media, especially microwave components for high-frequency devices, such as devices for shifting the phase of microwaves, tunable filters, tunable metamaterial structures, and electronic beam steering antennas, e.g. phased array antennas.
C09K 19/12 - Non-steroidal liquid crystal compounds containing at least two non-condensed rings containing at least two benzene rings at least two benzene rings directly linked, e.g. biphenyls
C09K 19/30 - Non-steroidal liquid crystal compounds containing at least two non-condensed rings containing saturated or unsaturated non-aromatic rings, e.g. cyclohexane rings
C09K 19/18 - Non-steroidal liquid crystal compounds containing at least two non-condensed rings containing at least two benzene rings linked by a carbon chain the chain containing carbon-to-carbon triple bonds, e.g. tolans
C09K 19/16 - Non-steroidal liquid crystal compounds containing at least two non-condensed rings containing at least two benzene rings linked by a carbon chain the chain containing carbon-to-carbon double bonds, e.g. stilbenes
57.
PHARMACEUTICAL COMPOSITION AND METHOD FOR ENHANCING SOLUBILITY OF POORLY SOLUBLE ACTIVE PHARMACEUTICAL INGREDIENTS
The present invention relates to pharmaceutical compositions using polymers as an excipient. Particularly, the invention relates to a pharmaceutical composition comprising polyvinyl alcohol which is suitable to enhance solubility of poorly soluble active pharmaceutical ingredients in aqueous media. The present invention also relates to a method for enhancing solubility of poorly soluble active pharmaceutical ingredients.
The present invention relates to a compound of formula UI
The present invention relates to a compound of formula UI
The present invention relates to a compound of formula UI
as defined in claim 1, to a liquid crystal medium comprising a compound of formula UI and to high-frequency components comprising these media, especially microwave components for high-frequency devices, such as devices for shifting the phase of microwaves, tunable filters, tunable metamaterial structures, and electronic beam steering antennas, e.g. phased array antennas.
C09K 19/30 - Non-steroidal liquid crystal compounds containing at least two non-condensed rings containing saturated or unsaturated non-aromatic rings, e.g. cyclohexane rings
C07C 331/28 - Isothiocyanates having isothiocyanate groups bound to carbon atoms of six-membered aromatic rings
The present disclosure relates to methods of releasing a target molecule from intein complexes comprising an intein-C tagged target molecule and intein-N polypeptides, by contacting the intein complexes with nitrogen containing heteroaromatic derivatives, and/or by increasing residence time of intein complexes in a medium effective to remove the target molecule. Modulating the pH further facilitates target release.
C09D 11/38 - Inkjet printing inks characterised by non-macromolecular additives other than solvents, pigments or dyes
C09D 11/037 - Printing inks characterised by features other than the chemical nature of the binder characterised by the pigment
C09D 11/033 - Printing inks characterised by features other than the chemical nature of the binder characterised by the solvent
C09D 11/101 - Inks specially adapted for printing processes involving curing by wave energy or particle radiation, e.g. with UV-curing following the printing
C09D 11/107 - Printing inks based on artificial resins containing macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds from unsaturated acids or derivatives thereof
The present invention relates to an organic electroluminescent device comprising a light-emitting layer comprising an electron-transporting host material and a hole-transporting host material, and to a formulation comprising a mixture of the host materials and to a mixture comprising the host materials. The electron-transporting host material corresponds to a compound of the formula (1) comprising diazadibenzofuran or diazadibenzothiophene units. The hole-transporting host material corresponds to a compound of the formula (2) from the class of the biscarbazoles or the derivatives thereof.
Transfer mechanism/device (40) transferring one or more objects (O) through a transfer port (R), having a supporting base (41), a shuttle (42) with a mount (43) for a holder (47) for the one or more objects (O) or with a holder (47) and a container (44) accommodating the base (41) and the shuttle (42) and accommodating the objects (O), and having at least one opening (45) at an end portion in an axial direction (X) of the container (44).
The present application relates to a rack (1) for holding a plurality of petri-dishes (P), comprising a plate-like main body (2) with a plurality of adjacent and spaced apart holding portions (3) each configured to receive and support, in a substantially horizontal orientation that is substantially perpendicular to a plane of the plate-like main body (2), a petri-dish (P), wherein each holding portion (3) includes positioning features (4) for positioning the petri-dish (P) in the holding portion (3).
The present application relates to a transfer device (60) for transferring a plurality of objects (O) through a transfer port (R), comprising a container (61) with an internal space (67) configured to accommodate the plurality of objects (O) to be transferred through the transfer port (R). The container (61) has at least one extraction opening (62) at an end portion of the container (61) in an axial direction (X) dimensioned such that the objects (O) can be removed from the container (61) at least individually, a door (63) configured to selectively close the at least one extraction opening (62) and seal the internal space (67) from the environment, and a piston (64) arranged in the container (61) so as to be movable in a translational motion in the axial direction (X) towards/away from the at least one extraction opening (62) to move the objects (O) accommodated in the container (61).
The present application relates to a transport packaging (20) for a plurality of petri-dishes (P), comprising a shell-like main body (21) with a compartment (22) for holding the plurality of petri-dishes (P) in a parallel orientation, the compartment (22) being accessible from an opening (23) at one side of the main body (21), and a rack-like structure (24) formed in the compartment (22) for supporting the petri-dishes (P) in a fixed position during handling and configured to allow insertion/extraction of the petri-dishes (P) into/from the rack-like structure (24) in a direction.
A liquid-crystal (LC) medium which is based on a mixture of polar compounds and is substantially dielectrically neutral, its use for optical, electro-optical and electronic purposes, in particular as optical retarder or optical compensator in LC displays, an optical retarder or optical compensator containing the LC medium, an optical, electrooptical or electronic device containing the optical retarder or optical compensator, and a process of manufacturing the optical retarder or optical compensator.
C09K 19/30 - Non-steroidal liquid crystal compounds containing at least two non-condensed rings containing saturated or unsaturated non-aromatic rings, e.g. cyclohexane rings
C09K 19/54 - Additives having no specific mesophase
C09K 19/12 - Non-steroidal liquid crystal compounds containing at least two non-condensed rings containing at least two benzene rings at least two benzene rings directly linked, e.g. biphenyls
The present invention relates to an organic electroluminescent device comprising a light-emitting layer comprising an electron-transporting host material and a hole-transporting host material, and to a formulation comprising a mixture of the host materials and to a mixture comprising the host materials. The electron-transporting host material corresponds to a compound of the formula (1) comprising diazadibenzofuran or diazadibenzothiophene units. The hole-transporting host material corresponds to a compound of the formula (2) from the class of the biscarbazoles or the derivatives thereof.
The invention relates to cyclic compounds which are suitable for use in electronic devices, and to electronic devices, in particular organic electroluminescent devices containing said compounds.
The present invention relates to the use of poloxamers as cell culture media additives. The poloxamers are suitable for foam reduction as well as for shear protection.
C09D 11/38 - Inkjet printing inks characterised by non-macromolecular additives other than solvents, pigments or dyes
B41M 5/40 - Thermography combined with layers or compositions suitable for other methods of image registration; Special originals for reproduction by thermography
71.
SURFACE-MODIFIED SILICA PARTICLES AND COMPOSITIONS COMPRISING SUCH PARTICLES
The present invention relates to surface-modified silica particles comprising an alkoxy organosilane and to compositions comprising such particles as well as to uses of such surface-modified silica particles and compositions comprising such particles.
A polysilazane having a ratio of the amount of SiH3 exceeding 0.050 and a ratio of the amount of NH of less than 0.045, based on the amount of aromatic ring hydrogen of xylene when 1H-NMR of a 17% by mass solution of polysilazane dissolved in xylene is measured. A siliceous film-forming composition comprising the polysilazane. A method for producing a siliceous film comprising applying the polysilazane composition above a substrate.
C08L 83/16 - Compositions of macromolecular compounds obtained by reactions forming in the main chain of the macromolecule a linkage containing silicon with or without sulfur, nitrogen, oxygen, or carbon only; Compositions of derivatives of such polymers in which all the silicon atoms are connected by linkages other than oxygen atoms
C09D 183/16 - Coating compositions based on macromolecular compounds obtained by reactions forming in the main chain of the macromolecule a linkage containing silicon, with or without sulfur, nitrogen, oxygen, or carbon only; Coating compositions based on derivatives of such polymers in which all the silicon atoms are connected by linkages other than oxygen atoms
73.
COMPOUNDS COMPRISING HETEROATOMS FOR ORGANIC ELECTROLUMINESCENT DEVICES
The present invention relates to cyclic compounds which are suitable for use in electronic devices, and to electronic devices, in particular organic electroluminescent devices containing said compounds.
The application relates to heterocyclic compounds of formulae (IV) to (VII), to the use of said compounds in an electronic device, and to methods for producing said compounds.
The present invention relates to a process of preparing polyfluoroether compounds with unsaturated end groups and to compounds prepared by said process.
C07C 41/16 - Preparation of ethers by reaction of esters of mineral or organic acids with hydroxy or O-metal groups
C07C 41/06 - Preparation of ethers by addition of compounds to unsaturated compounds by addition of organic compounds only
C07C 319/08 - Preparation of thiols, sulfides, hydropolysulfides or polysulfides of thiols by replacement of hydroxy groups or etherified or esterified hydroxy groups
76.
COMPOUNDS THAT CAN BE USED FOR STRUCTURING FUNCTIONAL LAYERS OF ORGANIC ELECTROLUMINESCENT DEVICES
The present invention relates to the use of compounds for structuring of at least one functional layer of an organic electronic device. The present invention further relates to preferred compounds suitable for use in electronic devices, and to electronic devices, especially organic electroluminescent devices, comprising these compounds.
H10K 85/60 - Organic compounds having low molecular weight
C07C 22/04 - Cyclic compounds containing halogen atoms bound to an acyclic carbon atom having unsaturation in the rings containing six-membered aromatic rings
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 251/24 - Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to three ring carbon atoms
C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
The present invention relates to cellulose based papers coated with nitrocellulose as well as to methods for producing such coated papers and methods for using them, especially in lateral flow applications.
B01D 69/02 - Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or properties; Manufacturing processes specially adapted therefor characterised by their properties
B01D 67/00 - Processes specially adapted for manufacturing semi-permeable membranes for separation processes or apparatus
A liquid crystal medium containing
a) one or more compounds of formula I
A liquid crystal medium containing
a) one or more compounds of formula I
b) one or more compounds of the formula IIBa
A liquid crystal medium containing
a) one or more compounds of formula I
b) one or more compounds of the formula IIBa
and c) one or more compounds of the formula IIDa
A liquid crystal medium containing
a) one or more compounds of formula I
b) one or more compounds of the formula IIBa
and c) one or more compounds of the formula IIDa
and the use thereof for optical, electro-optical and/or electronic purposes, in particular in LC displays, especially in IPS, FFS, VA or PS-VA displays.
C09K 19/34 - Non-steroidal liquid crystal compounds containing at least one heterocyclic ring
C09K 19/30 - Non-steroidal liquid crystal compounds containing at least two non-condensed rings containing saturated or unsaturated non-aromatic rings, e.g. cyclohexane rings
The present invention describes compounds having an acceptor group and a donor group, especially for use in electronic devices. The invention further relates to a process for preparing the compounds of the invention and to electronic devices comprising these.
H10K 85/60 - Organic compounds having low molecular weight
C07D 251/24 - Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to three ring carbon atoms
C07D 403/10 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing aromatic rings
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
C07D 409/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
C07D 413/10 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
C07D 491/048 - Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
C07D 209/86 - Carbazoles; Hydrogenated carbazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the ring system
80.
LMP7-SELECTIVE INHIBITORS FOR THE TREATMENT OF BLOOD DISORDERS AND SOLID TUMORS
Alpha-amino boronic acid derivatives are useful for selectively inhibiting the activity of immunoproteasome subunit LMP7 and for the treatment of medical conditions affected by immunoproteasome activity such as blood disorders and solid tumors, which are defined by specific genetic alterations and/or inadequate responsiveness to other therapeutic treatments. In particular, the compounds disclosed herein are selective LMP7 inhibitors, which may be useful alone or in combination for the treatment of blood disorders, such as multiple myeloma, and certain solid tumors.
The invention relates to a polymerizable LC material comprising one or more reactive mesogenic compounds, one or more chiral compounds and one or more compounds of formula I,
The invention relates to a polymerizable LC material comprising one or more reactive mesogenic compounds, one or more chiral compounds and one or more compounds of formula I,
The invention relates to a polymerizable LC material comprising one or more reactive mesogenic compounds, one or more chiral compounds and one or more compounds of formula I,
wherein the individual radicals have one of the meaning as given in the claims. Furthermore, the present invention relates also to a method for its preparation, a polymer film with improved thermal and UV stability obtainable from a corresponding polymerizable LC material, to a method of preparation of such polymer film, and to the use of such polymer film and said polymerizable LC material in optical, electro-optical, decorative or security devices.
A liquid-crystalline (LC) media having positive dielectric anisotropy and tliquid-crystal displays (LCDs) containing these media, especially to displays addressed by an active matrix and in particular to energy efficient LC displays of the TN, PS-TN, STN, TN-TFT, OCB, IPS, PS-IPS, FFS, HB-FFS, XB-FFS, PS-FFS, SA-HB-FFS, SA-XB-FFS, polymer stabilised SA-HB-FFS, polymer stabilised SA-XB-FFS, positive VA or positive PS-VA type.
G02F 1/137 - Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulating; Non-linear optics for the control of the intensity, phase, polarisation or colour based on liquid crystals, e.g. single liquid crystal display cells characterised by the electro-optical or magneto-optical effect, e.g. field-induced phase transition, orientation effect, guest-host interaction or dynamic scattering
C09K 19/34 - Non-steroidal liquid crystal compounds containing at least one heterocyclic ring
C09K 19/30 - Non-steroidal liquid crystal compounds containing at least two non-condensed rings containing saturated or unsaturated non-aromatic rings, e.g. cyclohexane rings
83.
COMBINED INHIBITION OF PD-1, TGFB AND TIGIT FOR THE TREATMENT OF CANCER
The present invention relates to combination therapies useful for the treatment of cancer. In particular, the invention relates to the combined use of a PD-1 inhibitor, a TGFβ inhibitor, and a TIGIT inhibitor to treat cancer.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present application relates to biotechnological fluid treating, such as biopharmaceutical liquids in order to obtain products such as monoclonal antibodies, vaccines or recombinant proteins, and particularly to a system for treating a biotechnical fluid, having a bioprocess machine and at least one bioprocess machine helper, configured to connect to each other and each comprising a controller, in turn comprising a machine-to-machine communication tool configured for connecting to a network
The present invention relates to a metal effect pigment-free radar-compatible coating on a substrate, to a process for the production of such a coating, and to the use of such a coating, in particular in vehicle construction.
The present invention relates to the use of meroxapols, also called “reverse poloxamers”, as cell culture media additives. The meroxapols are suitable for foam reduction as well as for shear stress protection.
Abstract: The present invention relates to compounds of the formula (1) which are suitable for use in electronic devices, in particular organic electroluminescent devices, and to electronic device.
Abstract: The present invention relates to compounds of the formula (1) which are suitable for use in electronic devices, in particular organic electroluminescent devices, and to electronic device.
The present invention relates to a solid pharmaceutical preparation of of 8-(1,3-Dimethyl-1 H-pyrazol-4-yl)-1-(Sa)-(3-fluoro-5-methoxy-pyridin-4-yl)-7-methoxy-3-methyl-1,3-dihydro-imidazo[4,5-c]quinolin-2-one, as well as a method of making same, as well as medical uses thereof.
A61K 31/4745 - Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
The present invention relates to metal complexes and to electronic devices, in particular organic electroluminescent devices, containing these metal complexes.
The present invention relates to a liquid-crystal material (LC media) comprising thiophene derivatives which are stabilised by sterically hindered amines or amine derivatives (HALS, hindered amine light stabilisers), and to liquid-crystal displays (LC displays) which contain these LC materials.
C09K 19/30 - Non-steroidal liquid crystal compounds containing at least two non-condensed rings containing saturated or unsaturated non-aromatic rings, e.g. cyclohexane rings
C09K 19/54 - Additives having no specific mesophase
The present application relates to compounds of formula (I) and (II), to processes for preparation thereof, and to the use thereof in electronic devices.
C07C 211/61 - Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings being part of condensed ring systems of the carbon skeleton with at least one of the condensed ring systems formed by three or more rings
C07D 209/86 - Carbazoles; Hydrogenated carbazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the ring system
C07C 211/54 - Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to two or three six-membered aromatic rings
A method can treat a patient suffering from at least one of fibrosis and a fibrotic disorder. The method includes administering a therapeutically effective amount of an anti-αv integrin antibody DI17E6, or a biologically active variant or modification thereof, to the patient.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
C12Q 3/00 - Condition-responsive control processes
A61P 17/02 - Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
A61P 11/00 - Drugs for disorders of the respiratory system
G01N 33/543 - Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
The present invention relates to immunoglobulins that specifically bind Aggrecan and more in particular to polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes. In particular, the immunoglobulins of the present invention inhibit the activity of Aggrecan.
Provided are immunoconjugates comprising bispecific anti-MUC 1/EGFR antibodies conjugated to hemiasterlin-based moieties via cleavable linkers, and pharmaceutical compositions thereof. Provided also are methods of treating cancer using such immunoconjugates and pharmaceutical compositions.
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present invention relates to an optical component comprising a liquid crystal (LC) medium, operable in the infrared region of the electromagnetic spectrum. The invention further relates to the use of said LC medium in the infrared (IR) region and to devices comprising said optical component. The present invention further relates to an LC medium comprising one or more compounds of the formulae I, II, and III
The present invention relates to an optical component comprising a liquid crystal (LC) medium, operable in the infrared region of the electromagnetic spectrum. The invention further relates to the use of said LC medium in the infrared (IR) region and to devices comprising said optical component. The present invention further relates to an LC medium comprising one or more compounds of the formulae I, II, and III
The present invention relates to an optical component comprising a liquid crystal (LC) medium, operable in the infrared region of the electromagnetic spectrum. The invention further relates to the use of said LC medium in the infrared (IR) region and to devices comprising said optical component. The present invention further relates to an LC medium comprising one or more compounds of the formulae I, II, and III
The present invention relates to an optical component comprising a liquid crystal (LC) medium, operable in the infrared region of the electromagnetic spectrum. The invention further relates to the use of said LC medium in the infrared (IR) region and to devices comprising said optical component. The present invention further relates to an LC medium comprising one or more compounds of the formulae I, II, and III
The present invention relates to an optical component comprising a liquid crystal (LC) medium, operable in the infrared region of the electromagnetic spectrum. The invention further relates to the use of said LC medium in the infrared (IR) region and to devices comprising said optical component. The present invention further relates to an LC medium comprising one or more compounds of the formulae I, II, and III
in which the occurring groups and parameters have the meanings defined in claim 1, and preferably one or more compounds of the formula RO
The present invention relates to an optical component comprising a liquid crystal (LC) medium, operable in the infrared region of the electromagnetic spectrum. The invention further relates to the use of said LC medium in the infrared (IR) region and to devices comprising said optical component. The present invention further relates to an LC medium comprising one or more compounds of the formulae I, II, and III
in which the occurring groups and parameters have the meanings defined in claim 1, and preferably one or more compounds of the formula RO
The present invention relates to an optical component comprising a liquid crystal (LC) medium, operable in the infrared region of the electromagnetic spectrum. The invention further relates to the use of said LC medium in the infrared (IR) region and to devices comprising said optical component. The present invention further relates to an LC medium comprising one or more compounds of the formulae I, II, and III
in which the occurring groups and parameters have the meanings defined in claim 1, and preferably one or more compounds of the formula RO
in which the occurring groups and parameters have the meanings defined in claim 2.
C09K 19/12 - Non-steroidal liquid crystal compounds containing at least two non-condensed rings containing at least two benzene rings at least two benzene rings directly linked, e.g. biphenyls
C09K 19/30 - Non-steroidal liquid crystal compounds containing at least two non-condensed rings containing saturated or unsaturated non-aromatic rings, e.g. cyclohexane rings
C09K 19/16 - Non-steroidal liquid crystal compounds containing at least two non-condensed rings containing at least two benzene rings linked by a carbon chain the chain containing carbon-to-carbon double bonds, e.g. stilbenes
C09K 19/18 - Non-steroidal liquid crystal compounds containing at least two non-condensed rings containing at least two benzene rings linked by a carbon chain the chain containing carbon-to-carbon triple bonds, e.g. tolans
C09K 19/34 - Non-steroidal liquid crystal compounds containing at least one heterocyclic ring
C09K 19/32 - Non-steroidal liquid crystal compounds containing condensed ring systems, i.e. fused, bridged or spiro ring systems
G02F 1/1334 - Constructional arrangements based on polymer-dispersed liquid crystals, e.g. microencapsulated liquid crystals
G02F 1/137 - Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulating; Non-linear optics for the control of the intensity, phase, polarisation or colour based on liquid crystals, e.g. single liquid crystal display cells characterised by the electro-optical or magneto-optical effect, e.g. field-induced phase transition, orientation effect, guest-host interaction or dynamic scattering
G02F 1/01 - Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulating; Non-linear optics for the control of the intensity, phase, polarisation or colour
METHOD FOR USING COMPOSITION COMPRISING CARBOXYLIC ACID ESTER, LITHOGRAPHY COMPOSITION COMPRISING CARBOXYLIC ACID ESTER, AND METHOD FOR MANUFACTURING RESIST PATTERN
To provide a chemically amplified resist composition capable of forming a resist pattern having high rectangularity. A chemically amplified resist composition comprising an alkali-soluble resin (A) having a certain structure and a cLogP of 2.76 to 3.35, a photoacid generator (B), and a solvent (C).
The invention relates to heteroaromatic compounds which are suitable for use in electronic devices, and to electronic devices, in particular organic electroluminescent devices, containing said compounds.
The invention relates to heterocyclic compounds which are suitable for use in electronic devices, and to electronic devices, in particular organic electroluminescent devices, containing said compounds.
C07D 491/22 - Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups , , or in which the condensed system contains four or more hetero rings
C07D 491/147 - Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom